Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy). One of the most effective weight loss medications ever developed.
Mechanism of Action
Semaglutide mimics GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via hypothalamic GLP-1 receptors.
Health Claims & Evidence
Significant and sustained weight loss
Improves glycemic control in type 2 diabetes
Reduces cardiovascular risk
Short-Term Effects
Reduced appetite within days, nausea initially, gradual weight loss.
Long-Term Effects
Significant sustained weight loss, improved metabolic markers, cardiovascular risk reduction.
Side Effects
Nausea, vomiting, diarrhea, constipation. Rare: pancreatitis, gallbladder disease.
Contraindications
Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Semaglutide and weight loss in obesity
Wilding et al. · New England Journal of Medicine · 2021
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Semaglutide and related peptides, and prepare an educational research summary.
Explore Research